United Therapeutics Corp.

Citadel Securities has upgraded United Therapeutics Corporation (NASDAQ: UTHR) from Neutral to Add and has raised the price target to $70.

Auriga has assumed coverage of United Therapeutics Corp. (NASDAQ: UTHR) at a Buy rating and with a price target of $90. According to Auriga, “We are assuming coverage of United Therapeutics (UTHR) with a Buy rating and a $90 price target. UTHR reported 1Q11 revenues that were once again below both...